Carsten Boess
Director/Board Member at ROCKET PHARMACEUTICALS, INC.
Net worth: - $ as of 29/04/2024
Carsten Boess active positions
Companies | Position | Start | End |
---|---|---|---|
ROCKET PHARMACEUTICALS, INC. | Director/Board Member | 31/12/2015 | - |
Independent Dir/Board Member | 31/12/2015 | - | |
AVIDITY BIOSCIENCES, INC. | Director/Board Member | 12/04/2020 | - |
Independent Dir/Board Member | 12/04/2020 | - | |
ACHILLES THERAPEUTICS PLC | Director/Board Member | 31/03/2020 | - |
Independent Dir/Board Member | 31/03/2020 | - | |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | 31/03/2020 | - |
Career history of Carsten Boess
Former positions of Carsten Boess
Companies | Position | Start | End |
---|---|---|---|
KINIKSA PHARMACEUTICALS, LTD. | Founder | 30/06/2015 | 31/01/2020 |
Corporate Officer/Principal | 30/06/2015 | 31/01/2020 | |
SYNAGEVA BIOPHARMA CORP | Director of Finance/CFO | 30/04/2011 | 31/12/2014 |
INSULET CORPORATION | Director of Finance/CFO | 31/05/2006 | 04/03/2009 |
Corporate Officer/Principal | 04/03/2009 | 31/12/2010 | |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | 31/12/2004 | 30/04/2006 |
ALEXION PHARMACEUTICALS, INC. | Director of Finance/CFO | 31/12/2003 | 31/12/2004 |
░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░ ░░░░░░░ ░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - |
░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | - | - |
Training of Carsten Boess
University of Southern Denmark | Graduate Degree |
Statistics
International
United States | 11 |
Denmark | 4 |
United Kingdom | 3 |
Operational
Director/Board Member | 6 |
Corporate Officer/Principal | 5 |
Independent Dir/Board Member | 5 |
Sectoral
Health Technology | 12 |
Consumer Services | 2 |
Process Industries | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 7 |
---|---|
INSULET CORPORATION | Health Technology |
NOVO NORDISK A/S | Health Technology |
KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
ROCKET PHARMACEUTICALS, INC. | Health Technology |
Health Technology | |
AVIDITY BIOSCIENCES, INC. | Health Technology |
ACHILLES THERAPEUTICS PLC | Health Technology |
Private companies | 7 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Novo Nordisk North America, Inc. | |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
Health Sciences Acquisitions Corp. 2
Health Sciences Acquisitions Corp. 2 Financial ConglomeratesFinance Health Sciences Acquisitions Corp. 2 is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on May 25, 2020 and is headquartered in New York, NY. | Finance |
- Stock Market
- Insiders
- Carsten Boess
- Experience